Charles River Laboratories International, Inc. $CRL Position Lessened by Integral Health Asset Management LLC

Integral Health Asset Management LLC reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 47.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,000 shares of the medical research company’s stock after selling 55,000 shares during the period. Integral Health Asset Management LLC owned about 0.12% of Charles River Laboratories International worth $9,388,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Neo Ivy Capital Management acquired a new stake in Charles River Laboratories International in the second quarter valued at approximately $29,000. Rothschild Investment LLC raised its holdings in shares of Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 84 shares in the last quarter. Atlantic Union Bankshares Corp bought a new position in shares of Charles River Laboratories International during the 3rd quarter valued at $31,000. Geneos Wealth Management Inc. lifted its stake in shares of Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares during the last quarter. Finally, Allworth Financial LP raised its stake in shares of Charles River Laboratories International by 172.7% in the 2nd quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 190 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on CRL. Argus set a $200.00 price objective on Charles River Laboratories International in a research report on Monday, November 17th. UBS Group raised their target price on Charles River Laboratories International from $170.00 to $175.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. Morgan Stanley set a $185.00 price target on shares of Charles River Laboratories International in a research report on Monday, December 1st. Robert W. Baird set a $193.00 price objective on shares of Charles River Laboratories International in a report on Thursday, February 19th. Finally, Mizuho dropped their target price on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research report on Friday, February 20th. Ten equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and a consensus price target of $203.57.

Charles River Laboratories International Stock Up 1.9%

Charles River Laboratories International stock opened at $155.61 on Friday. The company has a fifty day simple moving average of $191.59 and a 200 day simple moving average of $180.88. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $228.88. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. The company has a market cap of $7.66 billion, a P/E ratio of -52.57, a price-to-earnings-growth ratio of 2.61 and a beta of 1.64.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, beating the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The firm had revenue of $994.23 million during the quarter, compared to analysts’ expectations of $986.98 million. During the same period in the prior year, the firm posted $2.66 earnings per share. The business’s quarterly revenue was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International News Summary

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Zacks raised its FY2027 EPS view to $11.62 (from $11.30), signaling stronger full‑year outlook and supporting a higher valuation multiple. Zacks FY2027 boost
• Positive Sentiment: Zacks lifted FY2026 EPS to $10.78 (from $10.68), implying near‑term margin or revenue improvement versus prior assumptions. Zacks FY2026 boost
• Positive Sentiment: Zacks published FY2028 EPS of $12.12, reflecting continued expected earnings growth beyond FY2027. Long‑term upgrades can lift investor sentiment. Zacks FY2028 outlook
• Positive Sentiment: Multiple quarterly raises: Q3 2026 to $2.86, Q3 2027 to $3.02, Q4 2026 to $3.02, and Q4 2027 to $3.32 — these sequential upgrades point to improving quarterly momentum. Zacks quarterly upgrades
• Positive Sentiment: Zacks raised mid‑2026 quarterly views (Q2 2026 to $2.85 and Q2/Q3 2026 lifts), indicating expectations for recovery or stronger demand in the upcoming fiscal periods. Zacks mid‑2026 raises
• Neutral Sentiment: Zacks’ estimates differ from the consensus full‑year figure repeatedly cited ($9.36), meaning analyst views remain divergent; the Zacks upgrades imply upside versus consensus but do not change consensus itself. Consensus vs Zacks
• Negative Sentiment: Zacks lowered Q1 2026 EPS from $2.39 to $2.05, a material near‑term cut that could pressure the next quarter’s reported results and short‑term sentiment. Zacks Q1 2026 cut
• Negative Sentiment: Zacks slightly trimmed Q2 2027 to $2.65 (from $2.67), a minor downgrade but another signal of some variability in near‑term cadence. Zacks Q2 2027 trim

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.